drugset / Trial / NCT00734253
Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
Phase 2
Completed
317 enrolled
NephroGenex, Inc.
Collaborative Study Group (CSG) · collabMedpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary objective of this study is to evaluate the efficacy of two different doses of Pyridorin (150 mg and 300 mg)compared to placebo in retarding the progression of diabetic nephropathy. This will be assessed by measuring the change in serum creatinine and other biomarkers of kidney disease during the course of the 1-year study.
Timeline
- Start
- 2008-08
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyridorin | Unknown | 150 mg | Oral |
| Subject | Pyridorin | Unknown | 300 mg | Oral |